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Abstract Three minor-groove binding ligands have been used to
study the characteristics of two d(GAWCT)n DNAs embedded in
longer DNA fragments. The binding of mithramycin, netropsin
or Thia-Net to these sequences has been studied using DNAse I
footprinting. None of these ligands appeared to bind to
d(GAWCT)5 nor to d(GAWCT)22 extensively, although with
mithramycin some protected bonds were detected at the very
edge of these sequences. In general, these small ligands did not
enhance the DNAse I cleavage patterns at the alternating
d(GAWCT)n flanking sequences located near DNA regions where
the drug was bound. The d(GAWCT)n sequences could act as a
rigid block in which it is not easy to propagate structural
changes, whereas other sequences flanking the binding sites
showed cleavage enhancements.
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1. Introduction
Alternating d(GAWCT)n DNA sequences are quite abundant
in eukaryotic genomic DNA [1,2]. These sequences show an
outstanding degree of polymorphism that depends on envi-
ronmental conditions [3^6]. They are frequently found at re-
combination hot-spots [2], they can arrest DNA synthesis [7],
and they play a role in the increased genomic instability in
SV40 viruses [8]. Moreover, alternating d(GAWCT)n DNA se-
quences are often located in or near the regulatory regions of
many eukaryotic genes [2,9]. Some protein factors appear to
recognize d(GAWCT)n sequences [10,11]. Speci¢c molecular
recognition by protein factors is crucial in the regulation of
cell processes, while d(GAWCT) sequences of di¡erent length
might be a dubious binding site for some antitumor drugs [12]
that bind to the minor groove of DNA. Much e¡ort has been
dedicated to the development of drugs and related ligands
that could act as a compatible ¢tting with the base pairs along
the DNA [13,14]. Nevertheless, d(GAWCT)n sequences require
special consideration since they are remarkably polymorphic
[6]. The alternating conformation of this sequence [15], in
which DNAse I cuts the ApG and GpA steps di¡erently
[12,16], may become a potential handicap for geometrical ¢t-
ting along the minor groove.
Mithramycin, netropsin and Thia-Net are small compounds
that bind to the minor groove of DNA, though with di¡erent
sequence preferences. Mithramycin binds to GC-rich regions
in the presence of equimolar concentrations of Mg2
[12,17,18]. Netropsin binds to AT-rich regions in DNA that
contain clusters at least four bases long [19,20] and neither
guanine nor cytosine is allowed to interrupt it. Thia-Net is a
thiazole analog of netropsin [13,21] that binds better to four
base-pair long sites, mainly composed of A and T residues but
with a clear acceptance of intrusive GWC base pairs [21].
In this article we examine the interaction of netropsin, mi-
thramycin and Thia-Net with DNA fragments containing
d(GAWCT)5 and d(GAWCT)22 sequences. We analyze the ability
of these ligands to bind to or modify the alternating structure
of this polynucleotide.
2. Materials and methods
2.1. DNA binding drugs and enzymes
Mithramycin was purchased from Sigma, and netropsin from Serva.
Thia-Net was a generous gift from Dr. C.B. Bailly (CNRS, Lille,
France). The three drugs were stored at 320‡C as a 1 mM stock
solution in 10 mM Tris-HCl containing 20 mM NaCl. DNAse I
was purchased from Boehringer-Mannheim, prepared as 7200 units/
ml stock solution and diluted to working conditions immediately be-
fore use.
2.2. DNA substrates
d(GAWTC)5 and d(GAWTC)22 were kindly provided by Dr. M.L.
EspinaŁs (CSIC, Barcelona, Spain) as an insert in a pUC18 plasmid
carrying a modi¢ed polylinker [16]. The DNA fragments containing
the sequence to be analyzed were cleaved from the plasmid using
EcoRV and XhoI and puri¢ed by electrophoresis using 1% agarose
gels. The fragments were labeled at the XhoI site using the Klenow
enzyme and both [K-32P]dATP and [K-32P]dCTP.
2.3. DNAse I footprinting
Samples of the labeled DNA fragment (around 1 WM in base pairs)
were incubated with the appropriate drug solution ^ see Section 3 ^ at
30‡C for 20 min. In the experiments with mithramycin an equimolar
concentration of MgCl2 was added to the reaction mixture, since it is
required for drug binding [12,17,18]. The samples were then digested
(in a ¢nal volume of 6 Wl) with DNAse I at a ¢nal concentration of
0.01 units/ml. The enzymatic digestion was stopped by adding 3 Wl of
85% formamide containing 10 mM EDTA and 0.02% bromophenol
blue.
2.4. Gel electrophoresis and analysis of the results
The samples were heated at 90‡C for 2 min before electrophoresis.
The footprints were resolved by high voltage electrophoresis in 90
mM Tris/Borate, 2 mM EDTA (pH 8.3) bu¡er using 8% polyacryl-
amide gels containing 8 M urea, together with a formic acid-piperi-
dine marker speci¢c for guanines plus adenines. After running, the
gels were soaked in distilled water, and dried under vacuum and the
bands were observed by autoradiography. Analysis of the autoradio-
graphs was performed using a Molecular Dynamics computing densi-
tometer.
3. Results and discussion
Patterns of DNAse I digestion for the DNA fragment con-
taining a d(GAWCT)5 insert are shown in Fig. 1. The results
correspond to the strand that bears the GA tract. In the con-
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trol lanes (no added drug) the DNAse I digestion showed a
clear preference for cutting ApG over GpA. It is immediately
apparent that the cleavage patterns in the presence of the
ligands mithramycin (panel A), netropsin (panel B) or Thia-
Net (panel C) were substantially di¡erent from those of the
DNA alone. Nevertheless, the preference for cutting ApG
bonds over GpA in the large d(GAWCT) sequences was always
sustained. The footprints in regions other than the (GA)5
inserts were largely corroborative of the binding selectivity
of the three ligands to DNA, previously analyzed [12,18^21].
A summary map showing the di¡erence in susceptibility of
this DNA fragment to DNAse I in the presence of the higher
concentrations of the three ligands is displayed in Fig. 3A.
Fig. 1A presents DNAse I footprinting patterns of the
DNA fragment in the presence of increasing concentrations
of mithramycin. With 1 WM mithramycin the patterns of
DNAse I digestion remained essentially as in the control
lane. Higher concentrations (5^10 WM) produced clear sites
of drug protection that can be discerned along the DNA frag-
ment. Moreover, there are clear enhanced bands around them.
At higher concentrations (50 WM) a new protected region
appeared between bonds 140 and 152 and the region around
120 became wider. The protected region close to the
d(GAWCT)5 insert might re£ect the strong binding to the
GGG tract at the very edge of the GA tract, as substantiated
by the enhancements at the 109^111 nucleotides. At the higher
drug concentrations, the protected region covers about 3 bases
of the GA insert (bases 89^91). It is worth mentioning that
because DNAse I is a large molecule the sequence protected
from the enzymatic attack cannot be straightforwardly corre-
lated to the exact binding site [19,22]. The protected regions in
Figs. 1 and 3A might correspond to an indirect e¡ect due to
the accommodation in the minor groove of one of the saccha-
ride chains of mithramycin, rather than the direct recognition
of the sequence.
Visual inspection of the patterns of DNAse I cleavage in the
presence of di¡erent concentrations of netropsin, Fig. 1B,
revealed several well-resolved protected regions that contain
AT-rich sequences. Neither of these protected regions covered
the d(GAWCT)5 region, although concentrations of 10^15 WM
netropsin produced clear footprints in the neighboring re-
gions. At 15 WM the cleavage of some bonds at the middle
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Fig. 1. DNAse I footprinting of mithramycin, netropsin and Thia-Net on a DNA fragment containing a d(GAWCT)5 insert whose sequence is
shown in Fig. 3A. Panel A: (lane 1) A+G sequence ladder; (lane 2) control, no drug; (lanes 3^6) 1, 5, 10, 50 WM mithramycin. Panel B: (lane
1) A+G sequence ladder; (lane 2) control, no drug; (lanes 3^6) 1, 5, 10, 15 WM netropsin. Panel C: (lane 1) A+G sequence ladder; (lane 2)
control, no drug; (lanes 3^6) 1, 5, 10, 50 WM Thia-Net.
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of the GA sequence seems to be slightly diminished while the
£anking sequences at both sites remained unaltered (see Fig.
3A). A simple explanation for these protected bonds is a
weaker, secondary, netropsin binding site, since we do not
expect that netropsin could recognize the 2-amino group of
guanine [13,20]. The binding of increasing amounts of netrop-
sin produced weak enhancements at the vicinity of some bind-
ing sites, while the (GA)5 sequence did not show any symp-
tom of enhanced cleavage.
DNAse I footprinting with this DNA fragment showed
three well-resolved Thia-Net binding sites (Fig. 1C) that
were detected at concentrations higher than 5 WM. They con-
tain various isolated GA sites (Figs. 1 and 3A) in agreement
with previous studies [21]. In any case, Thia-Net had no e¡ect
on the pattern of DNAse I cleavage in the d(GAWCT)5 se-
quence. It is likely, therefore, that Thia-Net cannot recognize
the alternating helical twist pattern of this sequence [15],
though it accepts internal GWC pairs in the binding site [21].
Fig. 2 displays the cutting patterns produced by DNAse I
on the DNA fragment containing a (GAWCT)22 insert, in the
presence of di¡erent concentrations of mithramycin, netropsin
and Thia-Net. A protection map of the e¡ect of the three
ligands on this DNA is displayed in Fig. 3B. We shall pay
most attention to the possible binding of those drugs to the
d(GAWCT)22 inserts. We study the alterations (enhancements),
or binding in the neighboring regions, rather than the well-
known binding preferences of these ligands in more sequence-
averaged DNAs. In the control lanes (no added drug), the
DNAse I cleavage also exhibited the preference for cutting
ApG over GpA described above. The presence of any of the
three drugs did not signi¢cantly alter this pattern of cleavage.
At ¢rst glance, it seems that these drugs were not bound to
the d(GAWCT)22 tracts. They did not enhance the cleavage at
these tracts, nor did they change the di¡erential cutting at the
GpA and ApG steps. Broadly speaking, the binding sites that
can be identi¢ed for the three ligands (Figs. 2 and 3B) corre-
sponded to those previously described on other DNA frag-
ments [12,19,21]. Thia-Net protected regions that contain
short AG tracts from cleavage, for example around 130^136
(Fig. 2C), but it did not bind or alter the longer (GA)22 tract.
Likewise, our results indicate that this drug does not bind to
larger tracts containing strictly alternating GWC/AWT base
pairs.
The DNAse I footprinting analyzes suggest that mithramy-
cin (Fig. 2A) did not bind to the large GA tract within the
DNA fragment (see also Fig. 3B). Notwithstanding, clear
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Fig. 2. DNAse I footprinting of mithramycin (panel A), netropsin (panel B) and Thia-Net (panel C) on a DNA fragment containing a
d(GAWCT)22 insert whose sequence is shown in Fig. 3B. Panel A: (lane 1) A+G sequence ladder; (lane 2) control, no drug; (lanes 3^5) 1, 5, 10
WM mithramycin. Panel B: (lane 1) A+G sequence ladder; (lane 2) control, no drug; (lanes 3^6) 1, 5, 10, 15 WM netropsin. Panel C: (lane 1)
A+G sequence ladder; (lane 2) control, no drug; (lanes 3^7) 1, 5, 10, 50, 100 WM Thia-Net.
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strong binding sites were detected on both sides of the insert.
They correspond to zones containing CG-rich sequences, con-
sistent with the known sequence-selective binding of this drug
[12,17,18]. Besides, the cleavage at some £anking regions ap-
peared to be enhanced. The AG insert retained the preference
for cutting ApG over GpA as in the control ^ no added drug
^ experiments (Fig. 2A). At concentrations over 10 WM, a few
bonds close to the ends of the insert were slightly attenuated
in agreement with the results described above with the shorter
insert. This protected region might correspond to the minor-
groove alignment of one of the mithramycin saccharide seg-
ments on the £anking sides of the d(GAWCT)n tracts [18].
Unlike the (GA)5 insert, the (GA)22 one was mostly refractory
to both mithramycin binding and the indirect structural alter-
ation of its structure, in spite of the strong binding in the
neighboring zone, which is rati¢ed by the enhancements at
other regions around the binding sites (Fig. 2A). NMR studies
have shown that mithramycin binding makes the minor
groove both wider and deeper [17,18]. The propagation of
that change in the minor groove is small and it could some-
what depend on the length of d(GAWCT) tracts.
In general, binding of any of the three ligands produced
changes in the susceptibility of the £anking sequences to nu-
clease attack. Nevertheless, these changes did not take place at
the d(GAWCT)n inserts. If we assume that DNAse I cleavage
enhancements are mostly, but not exclusively, due to changes
in the DNA conformation [23], we should conclude that the
strong mithramycin binding at the edge of the d(GAWCT)
tracts was not capable of altering its structure extensively. A
possible explanation is that the alternating conformation of
these tracts [15], or the di¡erent structural properties in the
individual strands [3,5], could act as rigid block in which it is
not easy to propagate any structural change. It should be
remembered that these sequences can arrest DNA synthesis
[7], and they appear to be nucleosome-free in vivo [9]. How-
ever, it is worth noting that d(GAWCT)n sequences of di¡erent
length form nucleosomes in vitro [16].
Whereas we have identi¢ed the broad outlines of the drug
binding sites by DNAse I footprinting, it seems more di⁄cult
to interpret the small di¡erences seen at the very edge of the
d(GAWCT) tracts. We have also employed diethylpyrocarbon-
ate (DEPC) footprinting [24,25] to gain new insights into the
structural changes in long d(GAWCT) tracts after drug binding.
In the presence of mithramycin, a few bases near the drug
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Fig. 3. Protection maps showing the e¡ects of 50 WM mithramycin, 15 WM netropsin, and 50 WM Thia-Net on the DNase I footprinting of a
DNA fragment containing a d(GAWCT)5 insert (panel A) or of a DNA fragment containing a d(GAWCT)22 insert (panel B). Bars indicate se-
quences which are protected from cleavage. Broken bars indicate regions where the extent of protection was either weak or doubtful. Triangles
indicate enhanced cleavage in the presence of the ligands.
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binding sites displayed enhanced reactivity to DEPC, in agree-
ment with a previous report [25]. Notwithstanding, the weak
DEPC modi¢cation of the long d(GAWCT)n tracts remained
unaltered in the presence of any drug concentration (results
not shown).
In summary, none of the three drugs studied here binds
extensively to the d(GAWCT)n sequences, nor alters them sig-
ni¢cantly. They are minor-groove binding ligands that exem-
plify di¡erent sequence preferences. The analysis of their com-
plexes with DNA containing d(GAWCT) inserts indirectly
con¢rms the peculiar characteristics of this sequence.
Although the 2-amino group of guanines plays a key role as
regards the location of binding sites for minor-groove binders
like those analyzed here [26], the alternating polypurine se-
quences might, through their peculiar conformation, discrim-
inate between some small ligands. The future design of
d(GAWCT)n-reading molecules will demand that the character-
istic structure of these sequences be pondered carefully, espe-
cially the di¡erent conformation around the ApG and GpA
steps.
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